New hope for breast cancer bone metastases: drug duo targets tumors and bone loss

NCT ID NCT06374459

First seen Feb 16, 2026 · Last updated May 15, 2026 · Updated 15 times

Summary

This study tests a combination of two drugs (zunsemetinib and capecitabine) in people with a common type of breast cancer that has spread to the bones and cannot be cured. The goal is to see if the combo is safe and can slow cancer growth while also reducing bone damage. About 152 participants will take part in two phases to find the best dose and measure effects like tumor shrinkage and bone health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The University of Kansas Cancer Center

    RECRUITING

    Westwood, Kansas, 66205, United States

    Contact Phone: •••-•••-••••

    Contact

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.